文献速递肺结节与肺癌

高危患者低级别癌前支气管病变的内镜随访:SELEPREBB随机多中心试验长期结果

Endoscopic follow-up of low-grade precancerous bronchial lesions in high-risk patients: long-term results of the SELEPREBB randomised multicentre trial.
PubMed 文献 · Eur Respir J · 2022-09-15

SELEPREBB随机多中心试验纳入364例基线排除肺癌及重度鳞状异型增生或原位癌后的低级别支气管病变患者,比较标准随访与强化支气管镜监测,中位随访4.7年发现两组肺癌发生无差异,但基线轻中度异型增生显著增加肺癌风险,戒烟与病变清除及降低肺癌风险相关。

要点

  • 强化支气管镜监测未改善低级别癌前支气管病变患者的结局。
  • 基线轻中度异型增生是3年和最大随访时肺癌的显著危险因素。
  • 戒烟与支气管异型增生清除及5年肺癌风险降低显著相关。

核心结论

  • 轻中度异型增生患者5年肺癌风险很高,戒烟显著降低该风险。
  • 强化支气管镜监测不改善患者结局,但初始支气管镜识别异型增生或可用于肺癌筛查中的风险分层。

研究设计与样本

  • SELEPREBB为在17个法国中心开展的随机研究(ClinicalTrials.gov NCT00213603)。
  • 基线行肺部CT和自荧光支气管镜(AFB)排除肺癌及支气管重度鳞状异型增生或原位癌(CIS)后,患者随机分配至标准监测组(A组,36个月时CT和AFB)或强化监测组(B组,每6个月AFB)。
  • 共364例患者随机(A组180例,B组184例),进一步长期数据中位随访4.7年。

主要发现

  • 研究期间27例发生浸润性肺癌、2例发生持续CIS,两组间无差异(OR 0.63,95%CI 0.20-1.96,p=0.42)。
  • 基线支气管镜轻中度异型增生是3年肺癌显著危险因素(74例中8例,OR 6.9,95%CI 2.5-18.9,p<0.001)。
  • 基线轻中度异型增生在最大随访时也是肺癌显著危险因素(74例中16例,OR 5.9,95%CI 2.9-12.0,p<0.001)。
  • 戒烟与随访中支气管异型增生清除显著相关(OR 0.12,95%CI 0.01-0.66,p=0.005)。
  • 戒烟与5年肺癌风险降低显著相关(OR 0.15,95%CI 0.003-0.99,p=0.04)。

临床怎么用

  • 对轻中度支气管异型增生患者应强调戒烟以降低肺癌风险。
  • 强化支气管镜监测不改善结局,初始支气管镜识别异型增生可用于肺癌筛查风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 3-9% of low-grade preinvasive bronchial lesions progress to cancer. This study assessed the usefulness of an intensive bronchoscopy surveillance strategy in patients with bronchial lesions up to moderate squamous dysplasia. METHODS: SELEPREBB (ClinicalTrials.gov NCT00213603) was a randomised study conducted in 17 French centres. After baseline lung computed tomography (CT) and autofluorescence bronchoscopy (AFB) to exclude lung cancer and bronchial severe squamous dysplasia or carcinoma in situ (CIS), patients were assigned to standard surveillance (arm A) with CT and AFB at 36 months or to intensive surveillance (arm B) with AFB every 6 months. Further long-term data were obtained with a median follow-up of 4.7 years. RESULTS: 364 patients were randomised (A: 180, B: 184). 27 patients developed invasive lung cancer and two developed persistent CIS during the study, with no difference between arms (OR 0.63, 95% CI 0.20-1.96, p=0.42). Mild or moderate dysplasia at baseline bronchoscopy was a significant lung cancer risk factor both at 3 years (8 of 74 patients, OR 6.9, 95% CI 2.5-18.9, p<0.001) and at maximum follow-up (16 of 74 patients, OR 5.9, 95% CI 2.9-12.0, p<0.001). Smoking cessation was significantly associated with clearance of bronchial dysplasia on follow-up (OR 0.12, 95% CI 0.01-0.66, p=0.005) and with a reduced risk of lung cancer at 5 years (OR 0.15, 95% CI 0.003-0.99, p=0.04). CONCLUSION: Patients with mild or moderate dysplasia are at very high risk for lung cancer at 5 years, with smoking cessation significantly reducing the risk. Whereas intensive bronchoscopy surveillance does not improve patient outcomes, the identification of bronchial dysplasia using initial bronchoscopy maybe useful for risk stratification strategies in lung cancer screening programmes.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Guisier F, Deslee G, Birembaut P, et al. Endoscopic follow-up of low-grade precancerous bronchial lesions in high-risk patients: long-term results of the SELEPREBB randomised multicentre trial. Eur Respir J. 2022. PMID: 35236723. doi:10.1183/13993003.01946-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。